Adjuvant Chemotherapy in Premenopausal Breast Cancer Patients is Effective by Means Other than Ovarian Function Suppression

  • A. Goldhirsch
  • R. D. Gelber
  • M. Castiglione
Conference paper
Part of the ESO Monographs book series (ESO MONOGRAPHS)


In order further to clarify the role of endocrine mechanisms mediating the effect of adjuvant systemic therapy in patients with operable breast cancer, we analysed the incidence of amenorrhoea and its association with outcome in a cohort of 1127 premenopausal women included in a randomised trial. There were 4 distinct subpopulations defined by nodal status and therapy: in a group with node-negative disease (552 patients), one course of cytotoxic drugs was compared to no adjuvant chemotherapy. In a group with metastatic nodes (575 patients), a single course of cytotoxic therapy was compared with a prolonged treatment (6 or 7 courses). Amenorrhoea was defined as having no menstrual bleeding for a 3-month interval within the first 9 months after surgery. Amenorrhoea was observed in 21% of the 199 patients with N-negative breast cancer who received no adjuvant therapy, in 31% of the 353 N-negative patients who had a single course of cytotoxic therapy and in 31% of the 188 patients with N-positive disease who had the same short-duration therapy as compared to 68% of the 387 patients who had a prolonged adjuvant therapy. Amenorrhoea was associated with a prolonged disease- free survival (DFS) only in the patients with prolonged cytotoxic therapy: 4-year DFS % (+ s.e.) was 68% + 3% vs 61% + 5%, for the amenorrhoea and the no-amenorrhoea groups, respectively (p=0.05). On the other hand, the comparison between the effects of prolonged therapy upon outcome versus the short perioperative course (the direct comparison of the trial carried out within the node- positive population) showed a much larger treatment effect. The 4-year DFS% was 66% as compared to 38% (p<0.0001).

We conclude that cytotoxic-induced amenorrhoea is associated with a better outcome, but that this effect is difficult to observe due to the non cytotoxic-induced amenorrhoea rate, which is substantial in a patient population with breast cancer. The influence of amenorrhoea upon outcome is of small magnitude and it is unlikely that the effect of cytotoxics to reduce relapse and mortality rates in premenopausal women with breast cancer is primarily due to an ovarian suppression-mediated mechanism.


Breast Cancer Adjuvant Chemotherapy Oestrogen Receptor Status Cytotoxic Therapy Premenopausal Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Beatson GT: On the treatment of inoperable cases of carcinoma of the mammae: suggestions for a new method of treatment with illustrative cases. Lancet 1896 (ii): 104–107CrossRefGoogle Scholar
  2. 2.
    Goldhirsch A, Gelber RD, Mouridsen H: Adjuvant chemotherapy in premenopausal patients: a more complicated form of oophorectomy? In: Cavalli F (ed) Endocrine Therapy for Breast Cancer II. European School of Oncology Monographs. Springer Verlag, Berlin 1987 pp 11 -19Google Scholar
  3. 3.
    Henderson IC, Canellos GP: Cancer of the breast: the past decade. N Engl J Med 1980 (302):17–30PubMedCrossRefGoogle Scholar
  4. 4.
    Early Breast Cancer Trialists* Collaborative Group: Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. N Engl J Med 1988 (319):1681 -1692CrossRefGoogle Scholar
  5. 5.
    Fisher B, Sherman B, Rockette H et al: Lphenylalanine mustard (L-PAM) in the management of premenopausal patients with primary breast cancer: lack of association of DFS with depression of ovarian function. Cancer 1979 (44):847–857PubMedCrossRefGoogle Scholar
  6. 6.
    Bonadonna G, Valagussa P, Rossi A et al: Ten-year experience with CMF-based adjuvant chemotherapy in resectable breast cancer. Breast Cancer Res Treat 1985 (5):95–115PubMedCrossRefGoogle Scholar
  7. 7.
    Ludwig Breast Cancer Study Group: A randomized trial of adjuvant combination chemotherapy with or without prednisone in premenopausal breast cancer patients with metastases in one to three axillary lymph nodes. Cancer Res 1985 (45):4454–4459Google Scholar
  8. 8.
    Tormey DC: Adjuvant systemic therapy in postoperative node+ patients with breast carcinoma: the CALGB trial and the ECOG premenopausal trial. In Senn HJ (ed) Recent Results in Cancer Research. Adjuvant Chemotherapy of Breast Cancer. Springer Verlag, Heidelberg-Berlin 1984 pp 155–165Google Scholar
  9. 9.
    Padmanabhan N, Howell A, Rubens RD: Mechanisms of action of adjuvant chemotherapy in early breast cancer. Lancet 1986 (ii):411–414CrossRefGoogle Scholar
  10. 10.
    Brickner H, Mouridsen HT, Rank F et al: Evidence of a castration-mediated effect of adjuvant chemotherapy (CT) in a randomized trial of cyclophosphamide mono-therapy versus CMF in premenopausal stage II breast cancer. Proc Am Soc Clin Oncol 1985 (4):56Google Scholar
  11. 11.
    Valagussa P, Bonadonna G: Mechanism of action of adjuvant chemotherapy in early breast cancer. Lancet 1986 (ii):1035–1036CrossRefGoogle Scholar
  12. 12.
    Ludwig Breast Cancer Study Group: Combination adjuvant chemotherapy for node-positive breast cancer: inadequacy of a single perioperative cycle. N Engl J Med 1988 (319):677–683CrossRefGoogle Scholar
  13. 13.
    Ludwig Breast Cancer Study Group: Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for nodenegative breast cancer. N Engl J Med 1989 (320):491–496CrossRefGoogle Scholar
  14. 14.
    Anderson JR, Cain KC, Gelber RD: Analysis of survival by tumor response. J Clin Oncol 1989 (1):710–719Google Scholar
  15. 15.
    Kaplan EL, Meier P: Nonparametric estimation from incomplete observation. J Am Statist Assoc 1958 (53):457–481CrossRefGoogle Scholar
  16. 16.
    Peto R, Pike MC, Armitage P et al: Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Br J Cancer 1977 (35):1–39PubMedCrossRefGoogle Scholar
  17. 17.
    Cox DR: Regression models and life tables (with discussion). J R Stat Soc B (Methodology) 1972 (34): 187–220Google Scholar
  18. 18.
    Fisher B, Costantino J, Redmond C: A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 1989(320):479–484PubMedCrossRefGoogle Scholar
  19. 19.
    Kaufmann M, Jonat W, Caffier H, Kreienberg R, Hilfrich J, Abel U, Maass H, Kubli F: Adjuvant systemic risk adapted cytotoxic +/ tamoxifen therapy in women with node-positive breast cancer. In Salmon SE (ed) Adjuvant Therapy of Cancer. V. Grune &Stratton, Orlando 1987 pp 337–346Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1990

Authors and Affiliations

  • A. Goldhirsch
    • 1
    • 2
  • R. D. Gelber
    • 3
  • M. Castiglione
    • 4
  1. 1.Division of OncologyOspedale San GiovanniBellinzonaSwitzerland
  2. 2.Ospedale CivicoLuganoSwitzerland
  3. 3.Harvard Medical SchoolHarvard School of Public Health and Dana-Farber Cancer InstituteBostonUSA
  4. 4.Institute of Medical Oncology, InselspitalUniversity of BernBernSwitzerland

Personalised recommendations